Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.07+0.38 (+5.68%)
Close on Nov 18, 2026Market cap $466.98MP/E –Yield –
Evolus price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Evolus's price to sales ratio was 1.5× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 0.9× to 6.3×, with a median of 3.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.5× | +0.0 |
| 2025 | Dec 31, 2025 | 1.5× | −1.3 |
| 2024 | Dec 31, 2024 | 2.8× | −0.4 |
| 2023 | Dec 29, 2023 | 3.3× | +0.2 |
| 2022 | Dec 30, 2022 | 3.0× | −1.2 |
| 2021 | Dec 31, 2021 | 4.2× | +2.2 |
| 2020 | Dec 31, 2020 | 2.0× | −19.5 |
| 2019 | Dec 31, 2019 | 21.6× | – |
See a number that looks wrong?